Caris Life Sciences, Inc.(CAI)Earnings, Financials & Key Ratios

CAI•NASDAQ

$18.95

$31.69B mkt cap·Price updated May 6, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryDiagnostics and Omics Tools

AboutCaris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.Show more

Revenue$812M+97.0%
EBITDA$45M+121.7%
Net Income-$538M-90.8%
EPS (Diluted)-3.22-19.3%
EBITDA Margin5.56%+111.0%
Operating Margin5.56%+108.9%
Net Margin-66.25%+3.1%
ROE-93.18%
Debt/Equity0.00

Analysis→Technical→

CAI Key Insights

Caris Life Sciences, Inc. (CAI) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y sales CAGR of 14.3%

✗Weaknesses

✗Weak momentum: RS Rating 12 (bottom 12%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Expensive at 54.9x book value

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

CAI Price & Volume

Caris Life Sciences, Inc. (CAI) stock price & volume — 10-year historical chart

Loading chart...

CAI Growth Metrics

Caris Life Sciences, Inc. (CAI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years13.56%

5 Years14.28%

3 Years46.46%

TTM144.85%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-486.79%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-140.63%

Return on Capital

10 Years-15.93%

5 Years-36.69%

3 Years-55.71%

Last Year7.67%

CAI Recent Earnings

Caris Life Sciences, Inc. (CAI) EPS & revenue vs analyst estimates — last 3 quarters

Full history →

●Beat EPS 2/3 qtrs (67%)●Beat Revenue 2/3 qtrs (67%)

Q1 2026Latest

Feb 26, 2026

EPS

$0.28

Est $0.02

+1500.0%

Revenue

$293M

Est $240M

+21.8%

Q4 2025

Nov 5, 2025

EPS

$0.08

Est $0.08

+200.0%

Revenue

$217M

Est $281M

-22.8%

Q3 2025

Aug 12, 2025

EPS

$0.54

Est $0.21

-157.1%

Revenue

$181M

Est $138M

+31.8%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Feb 26, 2026	$0.28vs $0.02+1500.0%	$293Mvs $240M+21.8%
Q4 2025	Nov 5, 2025	$0.08vs $0.08+200.0%	$217Mvs $281M-22.8%
Q3 2025	Aug 12, 2025	$0.54vs $0.21-157.1%	$181Mvs $138M+31.8%

Based on last 3 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	FCF Yield	Debt / Equity
EXASExact Sciences CorporationDirect Competitor	20.02B	104.91	-95.37	17.69%	-6.4%	-8.66%	1.78%	1.05
ILMNIllumina, Inc.Direct Competitor	21.13B	139.07	25.52	-0.78%	19.43%	32.84%	4.41%	0.94
NTRANatera, Inc.Direct Competitor	28.44B	206.77	-135.14	56.75%	-14.61%	-24.69%	0.24%	0.16
GHGuardant Health, Inc.Direct Competitor	11.19B	89.52	-26.96	32.88%	-44.18%
FDMT4D Molecular Therapeutics, Inc.Direct Competitor	559.37M	9.71	-4.01	2301.95%	-164.43%	-31.75%		0.04
CDNACareDx, IncProduct Competitor	1.07B	20.70	-51.75	13.79%	-1.98%	-2.61%	3.38%	0.06
PACBPacific Biosciences of California, Inc.Product Competitor	476.93M	1.58	-1.48	-23.19%	-325.8%	-13.95%		1.33
CERTCertara, Inc.Product Competitor	1.01B	6.18	-618	8.75%	-0.38%	-0.15%	9.33%	0.01

Compare CAI vs Peers

Caris Life Sciences, Inc. (CAI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs EXAS

Most directly comparable listed peer for CAI.

Scale Benchmark

vs TMO

Larger-name benchmark to compare CAI against a more recognizable public peer.

Peer Set

Compare Top 5

vs EXAS, ILMN, NTRA, GH

CAI Income Statement

Caris Life Sciences, Inc. (CAI) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'22	Dec'23	Dec'24	Dec'25
Sales/Revenue	294.35M	348.39M	432.1M	416.54M	294.01M	258.49M	306.13M	412.26M	812.03M
Revenue Growth %	17.9%	18.36%	24.03%	-3.6%	-29.42%	-12.08%	18.43%	34.67%	96.97%
Cost of Goods Sold	156.86M	179.11M	218.47M	216.03M	109.86M	178.46M	216.82M	233.48M	0
COGS % of Revenue	53.29%	51.41%	50.56%	51.86%	37.36%	69.04%	70.83%	56.63%	-
Gross Profit	137.5M▲ 0%	169.29M▲ 23.1%	213.63M▲ 26.2%	200.51M▼ 6.1%	184.16M▼ 8.2%	80.02M▼ 56.5%	89.31M▲ 11.6%	178.78M▲ 100.2%	0▼ 100.0%
Gross Margin %	46.71%	48.59%	49.44%	48.14%	62.64%	30.96%	29.17%	43.37%	-
Gross Profit Growth %	9.21%	23.12%	26.19%	-6.14%	-8.16%	-56.55%	11.61%	100.18%	-100%
Operating Expenses	71.54M	63.62M	64.85M	70.23M	45.07M	395.78M	408.86M	435.9M	437.79M
OpEx % of Revenue	24.3%	18.26%	15.01%	16.86%	15.33%	153.11%	133.56%	105.74%	53.91%
Selling, General & Admin	35.68M	42.7M	50.3M	52.7M	27.31M	294.51M	291.48M	321.86M	392.47M
SG&A % of Revenue	12.12%	12.26%	11.64%	12.65%	9.29%	113.94%	95.21%	78.07%	48.33%
Research & Development	0	0	0	0	0	101.27M	116.88M	113.92M	45.31M
R&D % of Revenue	-	-	-	-	-	39.18%	38.18%	27.63%	5.58%
Other Operating Expenses	35.86M	20.92M	14.54M	17.53M	17.76M	0	500K	128K	0
Operating Income	65.96M▲ 0%	105.67M▲ 60.2%	148.78M▲ 40.8%	130.28M▼ 12.4%	139.09M▲ 6.8%	-315.76M▼ 327.0%	-319.55M▼ 1.2%	-257.12M▲ 19.5%	45.11M▲ 117.5%
Operating Margin %	22.41%	30.33%	34.43%	31.28%	47.31%	-122.16%	-104.38%	-62.37%	5.56%
Operating Income Growth %	-3.14%	60.21%	40.8%	-12.43%	6.76%	-327.02%	-1.2%	19.54%	117.55%
EBITDA	172.64M	218.93M	272.26M	244.21M	249.74M	-267.5M	-270.55M	-208.21M	45.11M
EBITDA Margin %	58.65%	62.84%	63.01%	58.63%	84.94%	-103.49%	-88.38%	-50.5%	5.56%
EBITDA Growth %	-5.32%	26.82%	24.36%	-10.3%	2.26%	-207.11%	-1.14%	23.04%	121.67%
D&A (Non-Cash Add-back)	106.68M	113.26M	123.48M	113.93M	110.65M	48.25M	49M	48.91M	0
EBIT	52.63M	110.25M	159.83M	134.37M	143.81M	-294.15M	-309.81M	-231.87M	0
Net Interest Income	0	0	0	-79.16M	-61.56M	-25.73M	-20.35M	-42.9M	0
Interest Income	0	0	0	0	0	947K	11.26M	7.12M	16.5M
Interest Expense	42.75M	53.05M	78.34M	79.16M	61.56M	26.68M	31.61M	50.02M	-56.85M
Other Income/Expense	-56.08M	-48.47M	-67.3M	0	-109.55M	-5.07M	-21.86M	-24.77M	-113.2M
Pretax Income	9.88M▲ 0%	57.2M▲ 479.1%	81.48M▲ 42.5%	55.21M▼ 32.2%	29.53M▼ 46.5%	-320.83M▼ 1186.3%	-341.42M▼ 6.4%	-281.89M▲ 17.4%	-68.09M▲ 75.8%
Pretax Margin %	3.36%	16.42%	18.86%	13.26%	10.04%	-124.12%	-111.53%	-68.38%	-8.38%
Income Tax	3.84M	-14.86M	2.89M	4.19M	1.8M	0	0	0	469.87M
Effective Tax Rate %	38.91%	-25.98%	3.54%	7.59%	6.09%	0%	0%	0%	-690.09%
Net Income	6M▲ 0%	72.06M▲ 1101.6%	78.6M▲ 9.1%	31.01M▼ 60.5%	27.73M▼ 10.6%	-320.83M▼ 1256.8%	-341.42M▼ 6.4%	-281.89M▲ 17.4%	-537.96M▼ 90.8%
Net Margin %	2.04%	20.68%	18.19%	7.44%	9.43%	-124.12%	-111.53%	-68.38%	-66.25%
Net Income Growth %	-77.65%	1101.6%	9.07%	-60.54%	-10.57%	-1256.84%	-6.42%	17.43%	-90.84%
Net Income (Continuing)	6M	72.06M	78.6M	31.01M	27.73M	-320.83M	-341.42M	-281.89M	-537.96M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)	0.31▲ 0%	3.68▲ 1087.1%	3.97▲ 7.9%	1.72▼ 56.7%	1.55▼ 9.9%	-1.57▼ 201.3%	-1.82▼ 15.9%	-2.70▼ 48.4%	-3.22▼ 19.3%
EPS Growth %	-75.78%	1087.1%	7.88%	-56.68%	-9.88%	-201.29%	-15.92%	-48.35%	-19.26%
EPS (Basic)	0.31	3.74	3.97	1.72	1.55	-1.57	-1.82	-2.70	-3.22
Diluted Shares Outstanding	19.39M	19.61M	19.82M	18.01M	17.95M	254.79M	254.66M	254.66M	1.67B
Basic Shares Outstanding	19.32M	19.25M	19.82M	18.01M	17.95M	254.79M	254.66M	254.66M	1.67B
Dividend Payout Ratio	-	-	4.15%	28.47%	63.84%	-	-	-	-

CAI Balance Sheet

Caris Life Sciences, Inc. (CAI) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'22	Dec'23	Dec'24	Dec'25
Total Current Assets	135.15M	140.34M	220.02M	499.13M	214.66M	516.04M	242.61M	215.73M	997.8M
Cash & Short-Term Investments	66.09M	65.48M	121.29M	46.46M	132.54M	409.62M	121.59M	66.15M	800.09M
Cash Only	46.13M	35.42M	45.31M	46.46M	53.55M	107.19M	56.4M	63.95M	797.8M
Short-Term Investments	19.96M	30.06M	75.97M	0	78.99M	302.43M	65.18M	2.2M	2.29M
Accounts Receivable	83.7M	100.66M	171.92M	159.68M	144.3M	40.23M	55.3M	88.24M	112.14M
Days Sales Outstanding	103.79	105.46	145.22	139.92	179.14	56.8	65.93	78.13	50.41
Inventory	0	0	0	0	0	46.96M	49M	39.57M	0
Days Inventory Outstanding	-	-	-	-	-	96.04	82.49	61.86	-
Other Current Assets	-14.64M	-25.8M	-73.19M	292.98M	-62.18M	5.88M	4.96M	8.2M	85.57M
Total Non-Current Assets	1.92B	2.29B	2.79B	2.4B	2.4B	201.38M	170.29M	128M	127.86M
Property, Plant & Equipment	1.81B	2.01B	2.27B	1.82B	1.78B	138.05M	147.51M	102.77M	63.17M
Fixed Asset Turnover	0.16x	0.17x	0.19x	0.23x	0.17x	1.87x	2.08x	4.01x	12.85x
Goodwill	15.79M	15.79M	15.79M	15.79M	0	19.34M	19.34M	19.34M	19.34M
Intangible Assets	9.69M	7.72M	5.73M	4.12M	0	0	0	0	0
Long-Term Investments	80.58M	246.45M	473.79M	495.49M	0	0	0	0	0
Other Non-Current Assets	7.15M	14.8M	31.05M	66.5M	616.65M	43.98M	3.43M	5.89M	45.35M
Total Assets	2.06B▲ 0%	2.43B▲ 18.2%	3.01B▲ 24.0%	2.9B▼ 3.7%	2.61B▼ 10.0%	717.42M▼ 72.5%	412.9M▼ 42.4%	343.73M▼ 16.8%	1.13B▲ 227.5%
Asset Turnover	0.14x	0.14x	0.14x	0.14x	0.11x	0.36x	0.74x	1.20x	0.72x
Asset Growth %	3.49%	18.21%	23.96%	-3.68%	-9.96%	-72.54%	-42.45%	-16.75%	227.48%
Total Current Liabilities	164.01M	259.93M	425.53M	287.41M	320.25M	136.91M	95.14M	165.42M	127.14M
Accounts Payable	13.8M	7.83M	7.37M	7.29M	3.67M	27.27M	26.68M	27.79M	39.21M
Days Payables Outstanding	32.12	15.96	12.31	12.32	12.18	55.77	44.91	43.45	-
Short-Term Debt	95.53M	132.05M	311.38M	218.09M	183.45M	52.79M	167K	60M	169K
Deferred Revenue (Current)	10.61M	7.81M	7.57M	6.41M	3.03M	1.43M	5.68M	7.47M	0
Other Current Liabilities	44.06M	112.24M	99.21M	55.62M	130.11M	22.65M	22.13M	30.69M	126.98M
Current Ratio	0.82x	0.54x	0.52x	1.74x	0.67x	3.77x	2.55x	1.30x	7.85x
Quick Ratio	0.82x	0.54x	0.52x	1.74x	0.67x	3.43x	2.04x	1.06x	7.85x
Cash Conversion Cycle	-	-	-	-	-	97.07	103.5	96.55	-
Total Non-Current Liabilities	1.43B	1.61B	1.89B	1.92B	1.59B	2.28B	2.46B	2.68B	421.21M
Long-Term Debt	1.38B	1.57B	1.85B	1.88B	1.56B	169.57M	166.11M	319.19M	0
Capital Lease Obligations	0	0	0	0	0	44.2M	44.41M	38.89M	0
Deferred Tax Liabilities	51.8M	35.85M	38.32M	35.38M	24.44M	0	0	0	0
Other Non-Current Liabilities	2.12M	0	0	5.62M	3.42M	2.07B	2.25B	2.32B	421.21M
Total Liabilities	1.6B	1.87B	2.31B	2.21B	1.91B	2.42B	2.56B	2.84B	548.36M
Total Debt	1.48B	1.7B	2.16B	2.1B	1.75B	270.87M	217.27M	424.26M	169K
Net Debt	1.43B	1.67B	2.11B	2.05B	1.69B	163.68M	160.87M	360.31M	-797.63M
Debt / Equity	3.23x	3.02x	3.08x	3.03x	2.49x	-	-	-	0.00x
Debt / EBITDA	8.55x	7.78x	7.93x	8.59x	6.99x	-	-	-	0.00x
Net Debt / EBITDA	8.28x	7.62x	7.76x	8.40x	6.78x	-	-	-	-17.68x
Interest Coverage	1.54x	1.99x	1.90x	1.65x	2.26x	-11.83x	-10.11x	-5.14x	-
Total Equity	457.5M▲ 0%	563.85M▲ 23.2%	701.13M▲ 24.3%	693.24M▼ 1.1%	702.24M▲ 1.3%	-1.7B▼ 342.4%	-2.14B▼ 26.0%	-2.5B▼ 16.5%	577.31M▲ 123.1%
Equity Growth %	-	23.24%	24.35%	-1.13%	1.3%	-342.38%	-26.02%	-16.5%	123.1%
Book Value per Share	23.59	28.76	35.38	38.49	39.12	-6.68	-8.42	-9.81	0.35
Total Shareholders' Equity	457.5M	563.85M	701.13M	693.24M	702.24M	-1.7B	-2.14B	-2.5B	577.31M
Common Stock	2K	2K	2K	2K	2K	138K	38K	38K	283K
Retained Earnings	324.58M	397.64M	471.11M	493.29M	503.32M	-1.68B	-2.12B	-2.47B	-2.55B
Treasury Stock	0	0	0	0	0	-330K	-330K	-330K	0
Accumulated OCI	-8.13M	-6.12M	-6.51M	-6.63M	-5.74M	1.7M	218K	210K	936K
Minority Interest	0	0	0	0	0	0	0	0	0

CAI Cash Flow Statement

Caris Life Sciences, Inc. (CAI) cash flow — operating, investing & free cash flow history

Line item	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'22	Dec'23	Dec'24	Dec'25
Cash from Operations	129.26M	155.19M	179.77M	254M	277.02M	-285.71M	-276.1M	-245.2M	83.16M
Operating CF Margin %	43.91%	44.55%	41.6%	60.98%	94.22%	-110.53%	-90.19%	-59.48%	10.24%
Operating CF Growth %	-12.29%	20.07%	15.84%	41.29%	9.06%	-203.14%	3.36%	11.19%	133.91%
Net Income	6M	72.06M	78.6M	31.01M	27.73M	-320.83M	-341.42M	-281.89M	-68.09M
Depreciation & Amortization	106.68M	113.26M	123.48M	113.93M	110.65M	48.25M	49M	48.91M	22.61M
Stock-Based Compensation	1.73M	2.09M	2.87M	2.76M	1.77M	22.9M	15.24M	18.64M	70.01M
Deferred Taxes	1.14M	-14.95M	2.47M	3.73M	1.37M	0	0	0	0
Other Non-Cash Items	-31.21M	73.47M	58.28M	-314.67M	452.8M	-13.78M	8.2M	-1.8M	58.62M
Working Capital Changes	44.92M	-90.74M	-85.92M	417.23M	-317.31M	-22.26M	-7.13M	-29.07M	0
Change in Receivables	-1.8M	-7.8M	-19.27M	3.86M	11M	-11.9M	-15.08M	-33.82M	-29.79M
Change in Inventory	72M	38.86M	138.85M	0	0	-11.1M	-4.43M	5.46M	0
Change in Payables	3.57M	-2.21M	15K	0	0	8.91M	7.17M	-226K	11.04M
Cash from Investing	-181.6M	-411.75M	-663.34M	-271.87M	-33.97M	-282.99M	214.77M	52.93M	-16.26M
Capital Expenditures	-251.25M	-502.18M	-812.84M	-319.14M	-219.45M	-42.26M	-22.32M	-8.44M	-16.26M
CapEx % of Revenue	85.36%	144.14%	188.12%	76.62%	74.64%	16.35%	7.29%	2.05%	2%
Acquisitions	-16.06M	0	0	0	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-
Other Investing	66.07M	66.36M	106.15M	47.27M	185.48M	0	0	0	0
Cash from Financing	46.6M	245.63M	512.35M	-108.48M	-249.88M	10.45M	10.13M	200.29M	664.99M
Debt Issued (Net)	0	0	0	0	0	-962K	10.57M	199.82M	0
Equity Issued (Net)	0	0	0	0	0	0	0	0	0
Dividends Paid	0	0	-3.26M	-8.83M	-17.71M	0	0	0	0
Share Repurchases	-9.18M	0	-40.87M	-34.12M	-7.95M	0	0	0	-113K
Other Financing	46.6M	245.63M	515.61M	-99.65M	-232.18M	11.41M	-435K	471K	664.99M
Net Change in Cash	-6.42M▲ 0%	-10.71M▼ 66.9%	28.77M▲ 368.6%	-2.74M▼ 109.5%	-6.74M▼ 145.5%	-558.25M▼ 8186.3%	-51.13M▲ 90.8%	8.02M▲ 115.7%	732.01M▲ 9026.2%
Free Cash Flow	-121.99M▲ 0%	-346.98M▼ 184.4%	-633.07M▼ 82.5%	-65.14M▲ 89.7%	57.57M▲ 188.4%	-327.96M▼ 669.7%	-298.42M▲ 9.0%	-253.64M▲ 15.0%	66.89M▲ 126.4%
FCF Margin %	-41.44%	-99.6%	-146.51%	-15.64%	19.58%	-126.88%	-97.48%	-61.52%	8.24%
FCF Growth %	49.6%	-184.43%	-82.45%	89.71%	188.37%	-669.71%	9.01%	15%	126.37%
FCF per Share	-6.29	-17.70	-31.94	-3.62	3.21	-1.29	-1.17	-1.00	0.04
FCF Conversion (FCF/Net Income)	21.55x	2.15x	2.29x	8.19x	9.99x	0.89x	0.81x	0.87x	-0.15x
Interest Paid	0	0	0	0	0	24.24M	15.78M	49.02M	0
Taxes Paid	0	0	0	0	0	0	0	0	0

CAI Key Ratios

Caris Life Sciences, Inc. (CAI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2015	2016	2017	2018	2019	2020	2022	2023	2024	2025
Return on Equity (ROE)	5.95%	1.31%	14.11%	12.43%	4.45%	3.97%	-	-	-	-93.18%
Return on Invested Capital (ROIC)	2.93%	2.65%	3.85%	4.42%	3.51%	4.06%	-55.33%	-	-	-
Gross Margin	50.43%	46.71%	48.59%	49.44%	48.14%	62.64%	30.96%	29.17%	43.37%	-
Net Margin	10.75%	2.04%	20.68%	18.19%	7.44%	9.43%	-124.12%	-111.53%	-68.38%	-66.25%
Debt / Equity	3.11x	3.23x	3.02x	3.08x	3.03x	2.49x	-	-	-	0.00x
Interest Coverage	1.89x	1.54x	1.99x	1.90x	1.65x	2.26x	-11.83x	-10.11x	-5.14x	-
FCF Conversion	5.49x	21.55x	2.15x	2.29x	8.19x	9.99x	0.89x	0.81x	0.87x	-0.15x
Revenue Growth	9.7%	17.9%	18.36%	24.03%	-3.6%	-29.42%	-12.08%	18.43%	34.67%	96.97%

CAI SEC Filings & Documents

Caris Life Sciences, Inc. (CAI) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 2, 2026·SEC

Material company update

Feb 26, 2026·SEC

Material company update

Jan 12, 2026·SEC

10-Q Quarterly Reports

FY 2025

Nov 5, 2025·SEC

FY 2025

Aug 12, 2025·SEC

CAI Frequently Asked Questions

Caris Life Sciences, Inc. (CAI) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Caris Life Sciences, Inc. (CAI) reported $812.0M in revenue for fiscal year 2025. This represents a 1589% increase from $48.1M in 2003.

Caris Life Sciences, Inc. (CAI) grew revenue by 97.0% over the past year. This is strong growth.

Caris Life Sciences, Inc. (CAI) reported a net loss of $538.0M for fiscal year 2025.

Dividend & Returns

Caris Life Sciences, Inc. (CAI) has a return on equity (ROE) of -93.2%. Negative ROE indicates the company is unprofitable.

Caris Life Sciences, Inc. (CAI) generated $32.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More CAI

Caris Life Sciences, Inc. (CAI) financial analysis — history, returns, DCA and operating performance tools

Full CAI Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Caris Life Sciences, Inc.(CAI)Earnings, Financials & Key Ratios

CAI Key Insights

✓Strengths

✗Weaknesses

CAI Price & Volume

CAI Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

CAI Recent Earnings

CAI Peer Comparison

Compare CAI vs Peers

vs EXAS

vs TMO

Compare Top 5

CAI Income Statement

CAI Balance Sheet

CAI Cash Flow Statement

CAI Key Ratios

CAI SEC Filings & Documents

8-K Announcements

10-Q Quarterly Reports

CAI Frequently Asked Questions

Explore More CAI

Full CAI Stock Analysis

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation